The goal of advanced cardiac life support (ACLS) is restoration of spontaneous cardiac activity leading to improved systemic and cerebral oxygen delivery.' Epinephrine, an integral component of For editorial comment see page 1315 ACLS, increases peripheral vascular resistance and coronary perfusion pressure, providing increased myocardial oxygen delivery.2 Animal and human studies have shown that doses of epinephrine greater than that recommended by ACLS guidelines further increase myocardial blood flow3 and the rate of return of spontaneous circulation.4'5 Nevertheless, improved rates of return of spontaneous circulation noted with higher doses5 '6 have not been associated with an increase in survival. 5'79 In fact, some studies have reported a deleterious effect of higher doses of epinephrine on survival from cardiac arrest.7 '9 To our knowledge, the cardiac and extracardiac effects of higher doses of epinephrine administered during human cardiac arrest have not been examined in the postresuscitation period. This may have significant impact on the lack of improved outcomes in previous studies despite higher initial resuscitation rates. The purpose of this study was to examine the effect of epinephrine given during cardiac arrest on postresuscitation hemodynamic, oxygen transport, and utilization variables in patients receiving standardized intensive care.
METHODS
This study was approved by the Institutional Review Board for Human Research. Adult patients presenting to the emergency department after a witnessed (by family or friends) nontraumatic, normothermic cardiopulmonary arrest over a 9-month period were entered into the study if resuscitated to a return of spontaneous circulation. Patients Hg or to optinmize Do2; norepinephrine, to maintain a MAP of greater than 70 mm Hg; and, dopamine, to maintain renal perfusion at the dose of 2 ,g/kg/min. Inotropes (dobutamine) and preload and afterload reducers (nitroglycerin or sodium nitroprusside) were used in an attempt to maximize Do2 to at least 15 mL/kg and Vo2 to 3.5 mL/kg.
For study purposes, cardiac arrest time intervals consist of the bystander CPR time interval (witnessed cardiac arrest until EMS arrival), BCLS time interval (EMS arrival on scene to arrival at emergency department), and ACLS time interval (emergency department arrival until return of spontaneous circulation). These data were obtained from EMS run sheets and family interviews. Epinephrine was given only during the ACLS time interval in the emergency department. The epinephrine dose represents the total cumulative dose given during ACLS until a return of spontaneous circulation was attained.
The patients remained a minimum of 6 h in the emergency department resuscitation unit and were transferred to the intensive care unit where intervention according to the standardized protocol was continued for at least 24 h. It is institutional practice to evaluate all patients who have suffered cardiac arrest for the futility of continuing aggressive therapy at 24 h. The decision to withdraw therapy at 24 h is based on the presence of irreversible brain damage, advanced directives, or family input. For study purposes, patients who lived longer than 24 h were considered to be survivors, and those who died within the first 24 h were considered to be nonsurvivors.
Statistical Methods
Data on clinical variables measured over the first 6 h are represented as three summary values: initial, mean, and maximum over the 6-h period. Descriptive statistics are presented as the mean ± SD in the two groups separated by the total cumulative epinephrine dose deemed to best predict survival at 24 h using receiver operating characteristic curve methods. The total cumulative epinephrine dose that maximized the sum of sensitivity and specificity was then established. Sensitivity was defined as the probability of classifying true nonsurvivors as nonsurvivors, and specificity was defined as the probability of classifying true survivors as survivors. Patients receiving less than or equal to and greater than this total cumulative epinephrine dose comprised group 1 and 2, respectively. Two-sample two-sided t tests or the equivalent Wilcoxon nonparametric tests were used to compare continuous clinical variables between groups 1 and 2. Associations between groups 1 and 2 and categorical factors were tested using x2 statistics. The p values were adjusted for multiple comparisons using Tukey's method. Spearman correlations of the total cumulative epinephrine dose with other continuous factors (for all patients) were calculated and tested for significance from zero. Fisher's z transformation test was used to evaluate the differences in the correlation coefficients between groups 1 and 2.
RESULTS
Two hundred twelve patients suffering from cardiac arrest presented to the emergency department from January through October 1992. The cardiac arrest management was evenly distributed over 14 board-certified emergency department physicians over the period of the study. Forty-nine patients, 24 women and 25 men, with a mean age of 60.7 ± 16.7 years were resuscitated to a return of spontaneous circulation, met entry criteria, and enrolled in the study.
A total cumulative dose of 15 mg was found to best predict outcome at 24 h using receiver operator curve characteristics (sensitivity 85% and specificity 60%). Patients receiving less than or equal to and greater than this total cumulative epinephrine dose comprised group 1 and 2, respectively. There were 20 patients in group 1 and 29 patients in group 2. The total dose of norepinephrine given by infusion-over the first 6 h of the postresuscitation period was higher in group 2, 1.1 ± 0.5 mg, compared with 0.5 ± 0.5 mg (p<0.04) in group 1. Eight patients (40%) of group 1 and 26 patients (90%) of group 2 were vasopressor dependent in the postresuscitation period (p<0.001).
There was no significant difference in body surface area, core temperature on presentation, age, or gender between the two groups ( Table 1 ). The presenting rhythm, bystander CPR, BCLS, and ACLS time intervals were also similar in both groups (Table 1) . Preexisting medical history (Table 2 ) and baseline organ function as determined by initial laboratory values (Table 3) were also similar in both groups. The lack of a significant difference in baseline laboratory The initial, mean, and maximal hemodynamic, oxygen transport, and oxygen variables between groups over the first 6 h after return of spontaneous circulation are shown in Table 4 The correlation between the total cumulative epinephrine dose given during ACLS with mean hemo- r=0.03,  p=0.82), BCLS (r=0.06, p=0.66) , and ACLS (r=0.07, p=0.60). This reflects both interphysician dosing variability and the lack of influence of the duration of cardiac arrest, a clinical parameter for estimation of epinephrine dose.
Lactic acid levels in groups 1 and 2 were 11.4 ± 3.8 and 14.2 ± 4.6 (p<0.03) at return of spontaneous circulation, 5.8 ± 2.4 and 10.6 ± 4.5 (p<0.001) at 6 h, respectively. The disappearance of lactic acid expressed as the difference between lactic acid concentration at return of spontaneous circulation minus the concentration at 6 h was 5.6 ± 3.6 mmol/L in group 1 compared with 3.6 ± 4.7 mmol/L in group 2 (p<0.02).
All patients survived for at least 6 h. Using survival at 24 h as the end point, there were 17 survivors (85%) in group 1 and 12 survivors (41%) in group 2 (p<0.002). Five survivors (three in group 1 and two in group 2) were eventually discharged alive; of these, three (two in group 1 and one in group 2) were neurologically intact.
DISCUSSION
The present study, performed on out-of-hospital patients who had suffered cardiac arrest, prospectively examined the hemodynamic, oxygen transport, and utilization variables in patients receiving significantly different doses of epinephrine as a result of empirical independent physician decisions made during the resuscitation attempt. The epinephrine dose that predicted 24-li survival with the greatest sensitivity and specificity was a total amount of less than 15 mg. Separating the patients according to this total epinephrine dose (which also closely corresponds to the 0.2 mg/kg dose used in previous human and animal studies) produces two patient groups of almost equal size. Since age, sex, premorbid health status, presenting rhythm, bystander CPR time, BCLS (EMS transport time), length of ACLS, and postresuscitation care were similar in both groups, it appears that epinephrine and in particularly large doses create significant physiologic alterations in the early postresuscitation period. These physiologic alterations are represented by a dose-dependent impairment of systemic hemodynamic, oxygen transport, and utilization.
Epinephrine dose/response animal studies show that doses many times the ACLS recommendations can optimize resuscitation rates.3'13'14 Subsequent human studies'5"16 and case reports17 have also reported improved resuscitation rates with higher doses of epinephrine (0.2 mg/kg or 14 mg/70 kg compared with standard dose), and a reported absence of significant complications for doses up to 198 mg. '2 Studies quantifying plasma epinephrine levels during cardiac arrest have reported some of the highest levels recorded in any pathologic state. Mean epinephrine levels (normal resting concentrations, 160 pmol/L)'8 reach 56,217,'9 829,616,20 12,400,000,21 and 2,144,99420 pmol/L, before epinephrine administration, and after doses of 1 mg, 10 mg, and 14 mg of epinephrine, respectively. Taking into consideration that the mean total doses used in previous cardiac arrest studies were 14 mg, 8 14.9 mg,14 17.8 mg,7 and 37 mg,5 the plasma levels achieved in the current high dose group (mean dose, 35.5 ± 26 mg) should be similar or even higher than previously measured levels. By comparison, the levels reported in patients with acute catecholamine crisis secondary to pheochromocytoma have ranged from 140,000 to 1,100,000 pmol/L.22 Norepinephrine levels are also increased after cardiac arrest approximately 32-fold over resting levels before catecholamine administration;'9 and over 90-fold following the administration of epinephrine.23 Thus, even in the low-dose groups, the expected levels of plasma epinephrine and norepinephrine during cardiac arrest may be compatible with a state of catecholamine toxicity from endogenous and exogenous contributions.
Blood pressure monitoring alone proved inadequate for detecting the physiologic alterations between groups 1 and 2 in the postresuscitation period. Patients receiving the higher doses of epinephrine (group 2) had MAPs similar to those receiving the lower doses (group 1) despite greater degrees of myocardial dysfunction, systemic vasoconstriction, lactic acidosis, impairment of Do2, and impairment of Vo2.
Pathophysiologic changes similar to those found in this study have been ascribed to catecholamine excess in settings other than cardiac arrest. These settings consist of patients with acute pheochromocytoma crisis and individuals receiving therapeutic and supratherapeutic doses of epinephrine. The most prominent manifestations of epinephrine toxicity include cardiomyopathy and myocarditis, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] ates (similar to free radicals) that potentiate the ischemic-reperfusion injury.54 '55 The inability of tissues to utilize oxygen (impairment of Vo2) after a physiologic insult has been shown to be highly predictive of outcome, particularly in the postresuscitation period.49 The first recognizable marker of an impairment of Vo2 is the presence of "venous hyperoxia" during continuous central and mixed venous oxygen measurement. This is represented by an exaggerated elevation in SvO2 on return of spontaneous circulation which may continue into the postresuscitation period and is noted immediately after boluses of epinephrine for hypotensive episodes. Venous hyperoxia is paradoxically accompanied by low Cl and Do2, whereas normally, a low Cl and Do2 is associated with an increase in OER (SvO2) decreased as a compensatory response to maintain Vo2. Group 1 and 2 began the postresuscitation period with both similar and pathologically low Vo2. It was group 2 that continued to have a low Vo2 despite therapeutic interventions.
The possible trigger for the impairment of Vo2 in the postresuscitation period is cessation of microcirculatory flow that precedes extraordinarily high catecholamine levels of cardiac arrest. This is supported by the extreme, similar, and appropriate increase in OER during CPR in group 1 Twenty patients were in cardiogenic shock (pulmonary capillary wedge pressure >18 mm Hg and cardiac index of less than 1.8 L/min/m2) immediately after a return of spontaneous circulation. Sixteen (80%) of these patients were in group 2 and 4 (20%) in group 1 (p=0.007). Cardiogenic shock continued to persist in 14 patients 6 h after return of spontaneous circulation. Twelve (86%) of these patients were in group 2 and 2 (14%) were in group 1 (p<0.002). The similar baseline organ function and values of cardiac isoenzymes between the two groups indicate the lack of a disproportion of acute or chronic myocardial dysfunction between the two groups as a cause for cardiogenic shock. This impairment of myocardial function translates into an impairment of Do2. An impairment of Do2 has prognostic significance as a Do2 of less than 8 mL/kg/min is associated with progressive lactic acidosis and death in cardiogenic shock. 67 The maximum Do2 obtained in group 2 was only 6.8 ± 2.2 mL/min/kg vs 10.6 ±4.9 in group 1 (p<0.002) during the first 6 h of the postresuscitation period.
This study also confirms previous findings of a 100% 24-h mortality in patients who fail to reach a Vo2 greater than 90 mL/min.m2 within the first 6 h of the postresuscitation period.49 Both groups began the postresuscitation period with a Vo2 of less than 90 mL/min.m2; however, 95% of group 1 and only 62% of group 2 reached a Vo2 of greater than 90 mL/min.m2 by the sixth hour of the postresuscitation period (p<0.016).
The present study individualizes the total cumulative epinephrine dose as a significant contributor to physiologic alterations observed in the postresuscitation period. These alterations may be mitigated by minimizing the total epinephrine dose needed for a return of spontaneous circulation. This is congruent with the escalating principle of present ACLS guidelines68 that attempt to aggressively titrate the epinephrine dose upwards with increasing duration of cardiac arrest while in effect minimizing the potential for toxic reactions. To accomplish this task more objectively (although impractical routinely), therapy should be titrated using invasive hemodynamic monitoring to optimize coronary perfusion pressure (aortic minus right atrial relaxation phase pressure).
The physiologic alterations created by higher doses of epinephrine in the postresuscitation period appear reversible. One patient who received up to 40 mg of epinephrine survived with aggressive diagnostic and therapeutic intervention. Thus, the therapeutic caveat of this study suggests that early diagnostic and therapeutic intervention must be instituted to mitigate the physiologic alterations in the postresuscitation period, especially in the face of the potential for catecholamine toxicity. For example, in the presence of cardiogenic shock, if intense systemic vasoconstriction is overburdening an already compromised myocardium, other means of augmenting myocar-dial function may be required. These therapeutic interventions possibly include mechanical assistance during and after cardiac arrest such as cardiopulmonary bypass, direct mechanical ventricular assist, or balloon pump counterpulsation and alternative pharmacologic agents.3234,36 In the absence of these interventions, circulatory support will necessarily rely on vasopressor agents, given in potentially toxic doses.
CONCLUSION
Epinephrine used in the resuscitation of out-ofhospital patients who have suffered cardiac arrest alters systemic hemodynamic, oxygen delivery, and utilization in the postresuscitation period. Persistence of these alterations correlates with the total cumulative epinephrine dose given during the resuscitation. In the absence of early diagnostic and therapeutic interventions in the postresuscitation period to mitigate these alterations, large doses of epinephrine may improve the rate of return of spontaneous circulation while contributing to eventual morbidity and mortality. The present observations may shed some light on the noted lack of improvement reported in previous survival studies that compared varying doses of epinephrine in cardiac arrest. Indeed, depending on the total dose, it appears that epinephrine use in out-of-hospital cardiac arrest truly represents a therapeutic "double-edged sword."
